6-丙基-1,3-苯并噻唑-2-胺 | 107726-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 6-丙基-1,3-苯并噻唑-2-胺
• 英文名称: 6-propylbenzo[d]thiazol-2-amine
• 英文别名: 6-propyl-1,3-benzothiazol-2-amine
• CAS: 107726-13-6
• 化学式: C₁₀H₁₂N₂S
• mdl: MFCD10689893
• 分子量: 192.285
• InChiKey: LBOPQKGVJMWWEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-guanidinothiazole-4-carboxylic acid succinimido ester hydrochloride 、 6-丙基-1,3-苯并噻唑-2-胺 在 对苯二酚 作用下， 以 various solvent(s) 为溶剂， 反应 6.0h， 以73.2%的产率得到2-(diaminomethylideneamino)-N-(6-propyl-1,3-benzothiazol-2-yl)-1,3-thiazole-4-carboxamide;hydrochloride
  参考文献：
  名称：

  Quantitative structure-activity relationships of antitumor guanidinothiazolecarboxamides with survival enhancement for therapy in the 3LL Lewis lung carcinoma model

  摘要：

  Guanidinothiazolecarboxamides (GTCs) are a novel class of antitumor agents found to be systemically active against experimental pulmonary metastases of 3LL Lewis lung carcinoma. A series of substituted benzothiazole GTCs were found to produce enhancement of survival in this model by using 8 days of intraperitoneal dosing initiated 2 days after intravenous tumor challenge. Quantitative structure-activity relationships have been discovered in the GTC series with survival enhancement correlated to substituent parameters. Optimal correlations were found between the probit transform of the drug-induced increased lifespan (ILS) and field and pi parameters. Among the most effective analogues in this series was N-(5-fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide (19).

  DOI：

  10.1021/jm00111a009
• 作为产物：
  描述：

  正丙胺 在 溴 、 硫氰酸铵 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 以33%的产率得到6-丙基-1,3-苯并噻唑-2-胺
  参考文献：
  名称：

  WO2007/107758

  摘要：

  公开号：

文献信息

• [EN] PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] DÉRIVÉ DE BENZOTHIAZOLE CONTENANT PHÉNYLIMIDE OU SON SEL ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
  申请人：YUHAN CORP

  公开号：WO2013043001A1

  公开（公告）日：2013-03-28

  The present invention provides a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  本发明提供了一种含有苯甲酰亚胺基的苯并噻唑衍生物或其药用可接受盐，以及其制备方法和包含其的药物组合物。所述含有苯甲酰亚胺基的苯并噻唑衍生物或其药用可接受盐可以选择性地抑制KRS和层粘连蛋白受体（LR）之间的蛋白质相互作用，从而抑制癌细胞的迁移。因此，含有苯甲酰亚胺基的苯并噻唑衍生物或其药用可接受盐可能被有益地应用于预防或治疗与癌细胞转移相关的疾病。
• PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：YUHAN CORPORATION

  公开号：US20150011528A1

  公开（公告）日：2015-01-08

  Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  提供一种含有苯基亚胺基的苯并噻唑衍生物或其药用可接受盐，以及其制备方法和包含相同的药物组合物。该含有苯基亚胺基的苯并噻唑衍生物或其药用可接受盐可以选择性地抑制KRS和层粘连蛋白受体（LR）之间的蛋白质相互作用，从而抑制癌细胞的迁移。因此，该含有苯基亚胺基的苯并噻唑衍生物或其药用可接受盐可能被有用地应用于预防或治疗与癌细胞转移相关的疾病。
• Antibacterial agents
  申请人：Biots Scientific Management Pty Ltd

  公开号：US08088791B2

  公开（公告）日：2012-01-03

  Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R1)— or ═N—; R1 is hydrogen or an optional substituent and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2—, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, or —N(CH2CH3)—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.

  式(I)的化合物具有抗菌活性： 其中R代表氢或1、2或3个可选取代基团；W为═C(R1)—或═N—；R1为氢或可选取代基团，R2为氢、甲基或氟；或R1和R2共同为—CH2—、—CH2CH2—、—O—或，在任一方向上，为—O—CH2—或—OCH2CH2—；R3为式-(Alk1)m-(Z)p-(Alk2)n-Q的基团，其中m、p和n独立地为0或1，但至少有一个为1，Z为—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—、—N(CH2CH3)—、—C(═O)—、—O—(C═O)—、—C(═O)—O—或具有3至6个环原子的可选取代的单环芳环或杂环基团；或具有5至10个环原子的可选取代的双环杂环基团；Alk1和Alk2为可选取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可以选择以或被—O—、—S—、—S(O)—、—S(O2)—、—NH—、—N(CH3)—或—N(CH2CH3)—终止或中断；Q为氢、卤素、腈或羟基或具有3至6个环原子的可选取代的单环芳环或杂环基团；或具有5至10个环原子的可选取代的双环杂环基团。
• PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS
  申请人：Alder Catherine Mary

  公开号：US20120058984A1

  公开（公告）日：2012-03-08

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.

  本发明涉及某些新型化合物。具体而言，本发明涉及公式（I）的化合物及其盐。本发明的化合物是激酶活性抑制剂，特别是Itk活性抑制剂。
• ANTIBACTERIAL AGENTS
  申请人：Brown David Ryall

  公开号：US20100173933A1

  公开（公告）日：2010-07-08

  Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R 1 )— or ═N—; R 1 is hydrogen or an optional substituent and R 2 is hydrogen, methyl, or fluorine; or R 1 and R 2 taken together are —CH 2 —, —CH 2 CH 2 —, —O—, or, in either orientation, —O—CH 2 — or —OCH 2 CH 2 —; R 3 is a radical of formula -(Alk 1 ) m -(Z) p -(Alk 2 ) n -Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk 1 and Alk 2 are optionally substituted C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O 2 )—, —NH—, —N(CH 3 )—, or —N(CH 2 CH 3 )—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.

  化学式为（I）的化合物具有抗菌活性：其中R代表氢或1、2或3个可选取代基；W是═C（R1）-或═N-；R1是氢或可选取代基，R2是氢、甲基或氟；或R1和R2一起取-CH2-、-CH2CH2-、-O-，或者，在任何方向上，取-O-CH2-或-OCH2CH2-；R3是公式-(Alk1)m-(Z)p-(Alk2)n-Q的基团，其中m、p和n独立地为0或1，但至少有一个为1，Z是-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-、-N（CH2CH3）-、-C（═O）-、-O-（C═O）-、-C（═O）-O-，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代双环杂环基团；Alk1和Alk2是可选取代的C1-C6烷基、C2-C6烯基或C2-C6炔基基团，可以以-O-、-S-、-S（O）-、-S（O2）-、-NH-、-N（CH3）-或-N（CH2CH3）-结尾或被中断；Q是氢、卤素、腈或羟基，或具有3至6个环原子的可选取代的单环碳环或杂环基团；或具有5至10个环原子的可选取代的双环杂环基团。